Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCOA1 | Q15788 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2141965 | 0.89 | GLA (0.42) | NCOA1NCOA3ALOX5APFEN1SCN9A | |
| Hydrochloric Acid SCHEMBL28045031 | 0.88 | GLA (0.41) | NCOA1NCOA3ALOX5APFEN1SCN9A | |
| SCHEMBL714264 | 0.85 | TSHR (0.48) | ALOX5APFEN1GLAPOLBGAA | |
| SCHEMBL15391549 | 0.84 | NCOA1 (0.48) | NCOA1NCOA3CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL22607085 | 0.82 | TSHR (0.45) | ALOX5APFEN1SCN9AGLAPOLB | |
| SCHEMBL21715809 | 0.81 | TRPA1 (0.43) | ALOX5APFEN1SCN9AGLAPOLB | |
| SCHEMBL31533686 | 0.80 | PDE3B (0.43) | ALOX5APFEN1SCN9AGLAPOLB | |
| SCHEMBL21715783 | 0.80 | TRPA1 (0.42) | ALOX5APFEN1SCN9AGLAPOLB | |
| SCHEMBL2026493 | 0.80 | BACE1 (0.51) | TSHRTAAR1 | |
| SCHEMBL21715812 | 0.79 | TSHR (0.40) | NCOA1ALOX5APFEN1SCN9AGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317092-A1 | TETRAZOLE CONTAINING COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-10-14 | — | — | US | disclosed |
| CN-108473426-A | Cyclic amine derivatives and its medical usage | 东丽株式会社 | 2018-08-31 | — | — | CN | disclosed |
| CN-103097353-B | Immunomodulator and anti-inflammatory compound | INCOZEN THERAPEUTICS PVT LTD | 2015-03-04 | — | — | CN | disclosed |
| CN-103097353-A | Novel immunomodulator and anti-inflammatory compounds | INCOZEN THERAPEUTICS PVT LTD | 2013-05-08 | — | — | CN | disclosed |
| WO-2013029338-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-03-07 | — | — | WO | disclosed |
| US-7410963-B2 | To treat diseases associated with abnormal regulation of intracellular cAMP and/or cGMP rate and abnormal regulation of neurotransmitter effect, with no perturbating effect on memory; autoinflammatory disorders; 3-(8-Methoxy-1-methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-benzonitrile | VIA PHARMACEUTICALS, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20070123519-A1 | Benzo-1,4-diazepin-2-one derivatives as phosphodiesterase pde2 inhibitors, preparation and therapeutic use thereof | BAY CITY CAPITAL LLC | 2007-05-31 | — | — | US | disclosed |
| EP-1697332-A1 | BENZO'1,4 ! DIAZEPIN-2-ONE DERIVATIVES AS PHOSPHODIESTERASE PDE2 INHIBITORS, PREPARATION AND THERAPEUTIC USE THEREOF | NEURO3D (FR) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005063723-A1 | BENZO`1,4 ! DIAZEPIN-2-ONE DERIVATIVES AS PHOSPHODIESTERASE PDE2 INHIBITORS, PREPARATION AND THERAPEUTIC USE THEREOF | NEURO3D (FR) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123519-A1 | Benzo-1,4-diazepin-2-one derivatives as phosphodiesterase pde2 inhibitors, preparation and therapeutic use thereof | PDE12, PDE2A, PDE3A | NCOA1 2994/4885NCOA3 3433/4885CYP19A1 517/4885 |
| US-20210317092-A1 | TETRAZOLE CONTAINING COMPOUNDS | TSLP, IL5, TRPA1 | NCOA1 1959/4885NCOA3 2190/4885CYP19A1 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.